Amryt Pharma Holdings Ltd represents important values and corporate philosophy focused on delivering innovative medical solutions. The company aims to improve the lives of patients with rare and orphan diseases by developing and commercializing transformative treatments. With patient-centricity at its core, Amryt Pharma strives to provide cutting-edge therapies and support systems worldwide. The company's values include integrity, scientific excellence, and collaboration. By working closely with healthcare professionals, regulatory bodies, and patient organizations, Amryt Pharma ensures the highest standards of quality, safety, and efficacy for its products. Through its visionary approach, Amryt Pharma Holdings Ltd continues to make significant contributions to the field of rare disease medicine.

Amryt Pharma Holdings Ltd is primarily present in various countries and regions across the globe. The company focuses on expanding its presence in key markets including the United Kingdom, Ireland, and the United States. With its strong commitment to international growth, Amryt Pharma Holdings Ltd is also active in other strategic regions such as Europe, Canada, and the Middle East. By strategically penetrating these markets, the company aims to enhance its global footprint and reach a broader customer base, facilitating the availability of its innovative pharmaceutical products to a wider audience.

Amryt Pharma Holdings Ltd has achieved several significant milestones in its journey. The company successfully acquired the exclusive rights to Lojuxta®, a treatment for a rare cholesterol disorder called homozygous familial hypercholesterolemia (HoFH). In addition, Amryt Pharma Holdings Ltd gained regulatory approval for Lojuxta® in multiple countries, including the United States and Europe. The company also expanded its portfolio through the acquisition of Aegerion Pharmaceuticals Inc. These milestones have strengthened Amryt Pharma Holdings Ltd's position as a leader in the rare and orphan disease space and have contributed to its continued growth and success in the pharmaceutical industry.

Amryt Pharma Holdings Ltd is a pharmaceutical company that specializes in developing and commercializing drugs for rare and orphan diseases. Established in 2015, Amryt Pharma is headquartered in Dublin, Ireland. The company focuses on acquiring, developing, and marketing treatments for rare conditions, with a particular emphasis on delivering innovative therapies to patients with limited treatment options. Amryt Pharma's portfolio includes drugs like Lojuxta and Myalept, which target specific rare diseases. The company aims to improve the lives of patients with rare diseases by developing and delivering effective and innovative treatment options. Amryt Pharma Holdings Ltd has quickly emerged as a key player in the pharmaceutical industry, offering hope to patients suffering from rare conditions.

The main competitors of Amryt Pharma Holdings Ltd in the market include pharmaceutical companies such as BioMarin Pharmaceutical Inc., Akcea Therapeutics Inc., Aegerion Pharmaceuticals Inc., and Retrophin Inc.

Amryt Pharma Holdings Ltd is primarily active in the pharmaceutical industry.

Amryt Pharma Holdings Ltd is a pharmaceutical company that focuses on developing and commercializing innovative treatments for rare and orphan diseases. Their business model revolves around identifying and acquiring promising drug candidates, conducting rigorous research and clinical trials, obtaining regulatory approvals, and commercializing their products globally. Amryt Pharma aims to address unmet medical needs and improve the lives of patients with rare diseases through its specialized therapies. With an emphasis on strategic partnerships and collaborations, they strive to bring effective and life-changing treatments to the market, contributing to the advancement of rare disease healthcare.

The Amryt Pharma Holdings P/E ratio is 99.1.

The Amryt Pharma Holdings P/S ratio is 61.24.

The AlleAktien quality score for Amryt Pharma Holdings is 5/10.

The expected Amryt Pharma Holdings revenue is 503.29 M USD.

The expected Amryt Pharma Holdings profit is 311.02 M USD.

The company Amryt Pharma Holdings Ltd is a global biopharmaceutical company headquartered in Dublin, Ireland. The company focuses on the development and commercialization of therapies for rare and life-threatening diseases. Amryt follows a vertically integrated business model and has control over the entire value chain, from in-house research and development team to sales and marketing. Amryt operates in three business segments: Commercial Products, R&D Programs, and Licensing. The Commercial Products segment includes a wide range of therapeutics developed for the treatment of rare diseases. One of the company's key products is Lojuxta (Lomitapide), a medication for the treatment of homozygous familial hypercholesterolemia. The medication has been approved in Europe and is now being distributed in various countries worldwide. In the R&D Programs segment, Amryt invests in the development of therapies targeting unmet medical needs. The company currently has two main programs in clinical development: a therapy for the treatment of Epidermolysis bullosa, a rare skin disease, and a therapy for the treatment of lipid disorders. Amryt also offers a wide range of licenses to promote partnerships with other pharmaceutical companies. The company follows a strategy of partnering and collaborating with leading academic research institutions to promote the research and development of new therapies. Licensing and marketing products in Europe, the US, and other countries are integral parts of the business plan. Amryt's business model is based on an efficient global value chain that covers all stages from discovery to marketing. The company has a clear positioning in the field of rare diseases and offers therapeutics tailored to the medical needs of this specific population group. Research and development of products are crucial aspects of Amryt's business model. The company continuously invests in R&D projects and expands its product portfolio to provide its customers with a comprehensive range of therapeutics. Amryt's marketing and sales efforts focus on building close relationships with medical professionals and patient groups affected by rare diseases. The company also relies on digital and social media to increase awareness of its products and spread its message. Overall, Amryt pursues a strong business model based on the growing demand for therapies for rare diseases. The company offers a broad range of products and vertical integration to provide its customers with a comprehensive value proposition. Through its continuous investments in R&D programs and partnerships, Amryt Pharma will continue to position itself as a leading provider of therapeutics for rare diseases.

Amryt Pharma Holdings pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for Amryt Pharma Holdings or the company does not pay out a dividend.

The ISIN of Amryt Pharma Holdings is GB00BKLTQ412.

The WKN of Amryt Pharma Holdings is A2PQ6T.

The ticker of Amryt Pharma Holdings is AMYT.L.

Over the past 12 months, Amryt Pharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amryt Pharma Holdings is expected to pay a dividend of 0 USD.

The current dividend yield of Amryt Pharma Holdings is .

Amryt Pharma Holdings pays a quarterly dividend. This is distributed in the months of .

Amryt Pharma Holdings paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

Amryt Pharma Holdings is assigned to the 'Health' sector.

To receive the latest dividend of Amryt Pharma Holdings from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

The last dividend was paid out on 9/26/2024.

In the year 2023, Amryt Pharma Holdings distributed 0 USD as dividends.

The dividends of Amryt Pharma Holdings are distributed in USD.